
June 16 (Reuters) - Milestone Pharmaceuticals Inc MIST.O:
MILESTONE PHARMACEUTICALS SUBMITS RESPONSE TO THE FDA’S CRL FOR CARDAMYST (ETRIPAMIL) NASAL SPRAY FOR PSVT FOLLOWING TYPE A MEETING
MILESTONE PHARMACEUTICALS INC - FDA TO DETERMINE ACCEPTANCE OF RESPONSE AND PDUFA DATE WITHIN 30 DAYS
MILESTONE PHARMACEUTICALS INC - REVIEW TIME EXPECTED TO BE WITHIN 2 OR 6 MONTHS FROM RESUBMISSION
MILESTONE PHARMACEUTICALS INC: BELIEVE TYPE A MEETING WITH FDA PROVIDED GUIDANCE TO SUBMIT RESPONSE TO CRL DIRECTLY AFTER MEETING